摘要
目的:总结奥拉西坦与吡拉西坦的药理作用,探讨奥拉西坦治疗脑卒中后认知功能障碍的临床疗效和安全性。方法:选取2012年1月-2013年12月本院收治的脑卒中后认知功能障碍患者100例,按照随机数字表法将其分为观察组和对照组,每组各50例。观察组给予奥拉西坦治疗,对照组给予吡拉西坦治疗,两组疗程均为6个月。观察两组治疗前后蒙特利尔认知评估量表(Mo CA)、简易智能量表(MMSE)及日常生活能力量表(ADL)评分的变化,并评价疗效及用药安全性。结果:两组治疗前的Mo CA、MMSE、ADL评分比较差异均无统计学意义(P>0.05)。治疗后,两组的Mo CA、MMSE、ADL评分均较治疗前明显改善,观察组的改善情况明显优于对照组,差异均有统计学意义(P<0.05);观察组的Mo CA、MMSE、ADL评分改善总有效率均明显高于对照组,差异均有统计学意义(P<0.05)。两组的不良反应发生率均较低,差异无统计学意义(P>0.05)。结论:奥拉西坦可明显改善脑卒中患者的认知功能,临床疗效优于吡拉西坦,且安全性较好。
Objective： To summarize the pharmacological effects of Oxiracetam and Piracetam, to explore the clinical efficacy and safety of Oxiraeetam in the treatment of the cognitive dysfunction after stroke.Method： 100 patients with cognitive dysfunction after stroke admitted to our hospital from January 2012 to December 2013 were selected and divided into the observation group and the control group according to random number table method, 50 cases in each group.The observation group was given Oxiracetam for treatment.The control group was given Piracetam for treatment, the course of the two groups was 6 months.The changes of the Montreal cognitive assessment scale （ MoCA ）, Mini mental state examination scale （ MMSE ） and Activities of daily living scale （ ADL ） score of the two groups before and after treatment were observed, and the curative effect and drug safety were evaluated. Result： The MoCA, MMSE, ADL scores of the two groups before treatment had no statistical significance differences （P〉0.05） .After treatment, the MoCA, MMSE, ADL scores of the two groups were improved obviously, the improvement above indexes in the observation group were significantly better than the control group, the differences were statistically significant （ P〈0.05 ） .The total effective rate for improvement of the MoCA, MMSE, ADL scores in the observation group were significantly higher than those in the control group, the differences were statistically significant （ P〈0.05 ） .The incidence of adverse reactions in the two groups were lower, and there was no statistically significant difference （P〉0.05） .Conclusion： The Oxiracetam can obviously improve the cognitive function of patients with stroke, the clinical curative effect is better than that of Piracetam, and has good security.
出处
《中国医学创新》
CAS
2016年第3期35-38,共4页
Medical Innovation of China
关键词
药理
认知功能障碍
奥拉西坦
临床应用
Pharmacology
Cognitive dysfunction
Oxiracetam
Clinical application
